Future-Proofing Canadian Healthcare: From Discovery to Delivery

We are in a once-in-a-generation moment in the evolution of the Canadian healthcare system. With rapid advancements in life sciences, particularly in fields such as gene editing, stem cell therapies, precision medicine, big data analytics and artificial intelligence (AI), and adaptive clinical trial design, Canada has a unique opportunity to take a global leadership role in healthcare innovation. However, to succeed, Canada must not only embrace the scientific discoveries of today but also ensure its talent pool, healthcare infrastructure, regulatory environment, and policies evolve in lockstep.

The Golden Age of Scientific Discovery

The current era has been described as a golden age of scientific discovery, driven by unprecedented breakthroughs in genomics, engineering biology, generative AI, vaccine technologies and cell and gene therapy. The speed at which messenger RNA vaccines were developed during the COVID-19 pandemic exemplifies how modern science is transforming healthcare. The implications of these advancements extend far beyond infectious diseases—today, life-saving treatments are being developed for chronic diseases, rare disorders, and previously untreatable cancers.

However, Canada faces a major challenge: it is stuck in what the Conference Board of Canada refers to as the “innovation paradox,” where Canada excels in public research and development and educating its population at the post-secondary level but lags in commercial successes and innovation-based economic growth.  Part of this is that our healthcare system is not equipped to efficiently integrate scientific advancements, especially not in a timely manner. Let’s face it: we are a risk-averse society, and Canada’s healthcare system has long been plagued with a reluctance to integrate innovation, whether we talk about modernized diagnostics, advanced therapeutics or processes. 

For Canada to future-proof our healthcare system and become a world leader in life sciences, we must invest in infrastructure that supports cutting-edge treatments, multidisciplinary talent, patient engagement and timely approval pathways of new therapies. This includes building a system that enables precision medicine, where treatments are tailored to individual patients based on their genetic makeup and includes advanced diagnostic and data integration capabilities across the healthcare system. Most importantly, as Ted Hewitt recently articulated, we need to focus on “human processes that enable the translation of ideas by recognizing the value of new technologies and understanding how new products will be received by potential consumers.” This must include perspectives from patients, regulators, and payers.

Speeding up Clinical Trials and Strengthening Innovation Ecosystems

A significant part of this transformation must include an overhaul of Canada’s approach to clinical trials. A clinical trial may be the only way for a Canadian suffering from a rare cancer to receive a potentially life-saving or life-prolonging therapy in time!

To compete globally for trial sites, Canada needs to speed up the trial start-up phase. This requires a unified and streamlined clinical trial approval process. A national portfolio system, which has been successful in other countries, would allow clinical trials to be conducted more efficiently across provinces, giving Canadian patients more timely access to experimental treatments. This change would not only save lives but also position Canada as a leader in clinical research, driving further investments in high-value jobs and new healthcare technologies.

Leveraging Artificial Intelligence for Healthcare

Artificial intelligence (AI) is another area in which Canada has the potential to be a global leader. The discovery of neural networks, which are the backbone for AI and for which Dr Geoffrey Hinton of the University of Toronto was recently awarded the Nobel Prize, will anchor Canada forever to its research strength in AI. However, we are already falling behind other nations when it comes to the application of AI in healthcare.

AI already has applications in accelerating drug discovery, optimizing healthcare delivery, writing clinical trial reports, and improving patient outcomes. For instance, Pfizer partnered with IBM’s AI to develop PAXLOVID, a treatment for COVID-19, significantly speeding up the drug design process. Most pharmaceutical companies, including Novartis and Roche, have also embraced AI to revolutionize drug development.

However, with this opportunity comes challenges. Canada must address the regulatory and ethical concerns surrounding AI in healthcare. AI relies heavily on data, and stringent data security and privacy regulations are necessary to ensure that patient information is protected while still allowing for the transformative benefits of AI. Developing a robust, AI-friendly regulatory framework will be critical to attracting further investment in this area and ensuring that Canada remains at the forefront of medical innovation.

Reducing Barriers to Access for Life-Saving Medications

One of Canada’s most pressing healthcare challenges is ensuring timely access to innovative diagnostics and therapies. The current system of listings on public drug plans is plagued by long approval times and limited or delayed access to new treatments compared to other G20 jurisdictions. This is particularly detrimental for patients with rare diseases and cancers, who often have no choice but to seek treatment abroad, draining their financial resources. 

We can learn from other countries that have approaches in place that provide immediate access to new treatments following regulatory approvals, while health technology assessment and price negotiations happen in parallel. Once a price is agreed upon, a reconciliation allows governments and manufacturers to recoup expenses and/or share risk. Most of all, this benefits patients who have faster access to the medicines they need. Another way to reduce barriers is through so-called outcomes-based agreements, where pharmaceutical companies are paid based on the effectiveness of the drugs they provide. This model has already been successfully implemented in countries like Germany and Australia and can help ensure that Canadians receive high-value treatments without unnecessarily inflating healthcare costs.

While our approach in Canada must be uniquely Canadian, we can lean on the vast experience with such systems elsewhere. A creative and national approach to drug listings would streamline the process, cutting down on delays and making Canada a more predictable business environment for new therapy launches.

At the provincial level, collaboration is key and greatly facilitated by the pan-Canadian Pharmaceutical Alliance. Here, provinces can work together, harmonize their drug listing processes, and eliminate the disparities that currently exist. For example, patients in Quebec can wait up to 547 days for a rare disease drug to be listed for coverage, while patients in Prince Edward Island may wait 1,301 days. Of course, provincial capacities and resources differ, but this inconsistency isn’t equitable. It not only delays appropriate treatment but also signals to global pharmaceutical companies that Canada is not a reliable market for launching new therapeutics.

Fostering a Collaborative Ecosystem

Collaboration across governments, healthcare providers, and the pharmaceutical industry is essential for driving innovation. The urgency of the pandemic created unprecedented collaboration in Canada and around the world along the entire value chain from discovery to development, regulatory approval and implementation. Today, we have all but lost this agility and speed.

Canada’s recent Council of the Federation meeting highlighted the importance of provinces working together to give Canadians the same timely access to life-saving treatments as patients in other developed countries. Ontario Premier Doug Ford’s call to action for faster approval processes is a step in the right direction and signals urgency. However, meaningful progress will require sustained efforts from the federal and provincial governments at both the political and public servant levels.

A Prescription for the Future

Canada has the scientific talent, innovative biotech and multinational companies, and research infrastructure to lead the world in life sciences. However, the country’s healthcare system must evolve to match the rapid pace of scientific discovery. By embracing new technologies like AI, streamlining clinical trials, accelerating drug approval processes, and fostering collaboration across stakeholders, Canada can position itself as a global leader in healthcare innovation. The stakes are high, but the benefits—both for individual Canadians and for the nation as a whole—are even higher.

It’s time for Canada to step up, seize this moment, and ensure that its healthcare system is built not only for today but for the future of medicine. Canadians deserve nothing less.